Invention Grant
- Patent Title: Mutant of L1 protein of human papillomavirus type 39
-
Application No.: US15734715Application Date: 2019-06-04
-
Publication No.: US11427618B2Publication Date: 2022-08-30
- Inventor: Shaowei Li , Daning Wang , Zhiping Wang , Xinlin Liu , Jun Zhang , Ningshao Xia
- Applicant: Xiamen University , Xiamen Innovax Biotech Co., Ltd.
- Applicant Address: CN Fujian; CN Fujian
- Assignee: Xiamen University,Xiamen Innovax Biotech Co., Ltd.
- Current Assignee: Xiamen University,Xiamen Innovax Biotech Co., Ltd.
- Current Assignee Address: CN Fujian; CN Fujian
- Agency: Barnes & Thornburg LLP
- Priority: CN201810563378.0 20180604
- International Application: PCT/CN2019/089988 WO 20190604
- International Announcement: WO2019/233415 WO 20191212
- Main IPC: C07K14/025
- IPC: C07K14/025 ; A61K39/12 ; C12N7/00 ; C12N15/70 ; A61K39/00

Abstract:
The invention relates to a mutated HPV39 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV39 and HPV68, or HPV39, HPV68 and HPV70), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
Public/Granted literature
- US20210198322A1 Mutant of L1 Protein of Human Papillomavirus Type 39 Public/Granted day:2021-07-01
Information query